Welcome to Counterpoint Biomedica

Counterpoint Biomedica LLC is a preclinical stage bio-pharmaceutical company engaged in basic Research, Development, and Commercialization of high-value tumor-targeted Oncology Products. The mission of the company is to enhance the performance of the most widely-used FDA-approved Chemotherapeutic and Biological Agents (APIs) by the addition of Pro-Active Tumor Targeting; and further, to apply these platform biotechnologies to Cancer Diagnostics and Liquid Biopsies. Founded by two board-certified oncologists and an award-winning research scientist from The University of Southern California School of Medicine, Counterpoint Biomedica LLC either owns outright or has gained exclusive patent rights to develop and / or to license these advanced proprietary tumor-targeting platforms for a wide variety of clinical applications. see White Paper.

Product pipeline

Focused sharply on oncology products, the company has developed an extensive and complementary pipeline that creates significant opportunities in terms of combination therapies with the added advantages of precision tumor-targeted drug delivery.

The addition of pro-active tumor targeting to FDA-approved drugs results in a significant reduction in the clinical development costs and timeline, while providing improved clinical efficacy and thus a commercial edge in marketing. Moreover, the addition of pro-active tumor targeting enables the approved anticancer agents (approved APIs) to perform with even greater therapeutic safety and efficacy, at lower drug doses, in the clinic.

Expertise in tumor-targeted drug delivery

Credited historically with the design engineering and clinical development of the first targeted and injectable gene delivery vehicle to be validated in clinical trials — employing a physiological drug delivery platform referred to as Pathotropic (disease-seeking) Targeting or XC-Targeting (exposed collagenous signatures— the Mission of Counterpoint Biomedica LLC Research and Development is/was to successfully engineer these powerful and proven biotechnology platforms for the enhancement of tumor-targeted drug delivery, improvement of conventional cancer therapeutics, and new precision cancer diagnostics.

In 2019, Counterpoint Biomedica LLC assisted in the restoration of DeltaRex-G to the Cancer Clinic.

Recently, Counterpoint Biomedica LLC gained New Patents for (1) Targeting Pharmaceutical Agents, (2) Capture and Characterization of Cancer Stem Cells, (3) Targeted Immuno-therapy, respectively.